Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 4/20 | 0.57 |
| ▸ | BACE1 | P56817 | 11/20 | 0.53 |
| ▸ | NCK1 | P16333 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 5/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389588 | 0.87 | PLAU (0.55) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL2671474 | 0.87 | PLAU (0.55) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL5873677 | 0.87 | PLAU (0.55) | PLAUBACE1NCK1NCF1NOS2 | |
| Potassium SCHEMBL4980046 | 0.85 | PLAU (0.54) | PLAUBACE1NCK1NCF1 | |
| SCHEMBL4980037 | 0.85 | PLAU (0.54) | PLAUBACE1NCK1NCF1 | |
| SCHEMBL4403751 | 0.85 | BACE1 (0.55) | PLAUBACE1NCK1NCF1NOS2 | |
| Hydrochloric Acid SCHEMBL4680889 | 0.85 | PLAU (0.54) | PLAUBACE1NCK1NCF1 | |
| Potassium Ion SCHEMBL3231217 | 0.84 | PLAU (0.52) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL23535667 | 0.81 | HTT (0.59) | PLAUBACE1NCK1NCF1 | |
| SCHEMBL4149851 | 0.81 | BACE1 (0.50) | PLAUBACE1NCK1NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | PLAU 4780/4885BACE1 1078/4885NCK1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.